[go: up one dir, main page]

WO2008087329A3 - Nouveau médicament pour le traitement d'un cancer gastrique - Google Patents

Nouveau médicament pour le traitement d'un cancer gastrique Download PDF

Info

Publication number
WO2008087329A3
WO2008087329A3 PCT/FR2007/052575 FR2007052575W WO2008087329A3 WO 2008087329 A3 WO2008087329 A3 WO 2008087329A3 FR 2007052575 W FR2007052575 W FR 2007052575W WO 2008087329 A3 WO2008087329 A3 WO 2008087329A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
treating gastric
new drug
drug
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/052575
Other languages
English (en)
Other versions
WO2008087329A2 (fr
Inventor
Pierre Miossec
Myew-Ling Toh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Hospices Civils de Lyon HCL
Original Assignee
Biomerieux SA
Hospices Civils de Lyon HCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA, Hospices Civils de Lyon HCL filed Critical Biomerieux SA
Priority to EP07871986A priority Critical patent/EP2091611A2/fr
Priority to US12/312,774 priority patent/US20100055108A1/en
Publication of WO2008087329A2 publication Critical patent/WO2008087329A2/fr
Publication of WO2008087329A3 publication Critical patent/WO2008087329A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'au moins un inhibiteur de l'interleukine 17 et/ou 5 d'au moins un inhibiteur d'un récepteur de l'IL17, pour la préparation d'un médicament destiné à l'inhibition, la prévention ou le traitement d'un cancer gastrique.
PCT/FR2007/052575 2006-12-21 2007-12-20 Nouveau médicament pour le traitement d'un cancer gastrique Ceased WO2008087329A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07871986A EP2091611A2 (fr) 2006-12-21 2007-12-20 Nouveau médicament pour le traitement d'un cancer gastrique
US12/312,774 US20100055108A1 (en) 2006-12-21 2007-12-20 Drug for treating gastric cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0655835A FR2910324B1 (fr) 2006-12-21 2006-12-21 Nouveau medicament pour le traitement d'un cancer gastrique
FR0655835 2006-12-21

Publications (2)

Publication Number Publication Date
WO2008087329A2 WO2008087329A2 (fr) 2008-07-24
WO2008087329A3 true WO2008087329A3 (fr) 2008-11-27

Family

ID=38222271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/052575 Ceased WO2008087329A2 (fr) 2006-12-21 2007-12-20 Nouveau médicament pour le traitement d'un cancer gastrique

Country Status (4)

Country Link
US (1) US20100055108A1 (fr)
EP (1) EP2091611A2 (fr)
FR (1) FR2910324B1 (fr)
WO (1) WO2008087329A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
TW201117824A (en) * 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
NO2523688T3 (fr) 2010-01-15 2018-03-10
WO2011141823A2 (fr) * 2010-05-14 2011-11-17 Orega Biotech Méthodes de traitement et/ou de prévention de troubles de prolifération cellulaire à l'aide d'antagonistes de il-17
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054059A1 (fr) * 2004-11-19 2006-05-26 Ucb Pharma S.A. Neutralisation de molecules d'anticorps presentant une specificite pour l'il-17 humaine
WO2006088833A2 (fr) * 2005-02-14 2006-08-24 Wyeth Anticorps de l'interleukine-17f et d'autres antagonistes de signalisation de l'il-17f et leurs utilisations correspondantes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054059A1 (fr) * 2004-11-19 2006-05-26 Ucb Pharma S.A. Neutralisation de molecules d'anticorps presentant une specificite pour l'il-17 humaine
WO2006088833A2 (fr) * 2005-02-14 2006-08-24 Wyeth Anticorps de l'interleukine-17f et d'autres antagonistes de signalisation de l'il-17f et leurs utilisations correspondantes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIZUNO T ET AL: "Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization", WORLD JOURNAL OF GASTROENTEROLOGY 28 OCT 2005 CHINA, vol. 11, no. 40, 28 October 2005 (2005-10-28), pages 6305 - 6311, XP009086507, ISSN: 1007-9327 *
YOU ZONGBING ET AL: "Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer", CANCER RESEARCH, vol. 66, no. 1, January 2006 (2006-01-01), pages 175 - 183, XP002442246, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
FR2910324A1 (fr) 2008-06-27
US20100055108A1 (en) 2010-03-04
EP2091611A2 (fr) 2009-08-26
FR2910324B1 (fr) 2009-03-06
WO2008087329A2 (fr) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2008079988A3 (fr) Quinazolines destinés à l'inhibition de pdk1
WO2007019251A3 (fr) Inhibiteurs de la sphingosine kinase et leurs methodes d'utilisation
WO2009126863A3 (fr) Inhibiteurs pyridiles de signalisation hedgehog
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
IL250858B (en) A tetracycline compound, a pharmaceutical composition comprising the tetracycline compound, and the tetracycline compound or the pharmaceutical composition for treating a tetracycline responsive state
PL2029642T3 (pl) Kompozycja katalizatora do kopolimeryzacji propylenu
WO2005079756A3 (fr) Methodes et compositions de traitement de troubles psychiatriques
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2008019115A3 (fr) Formulations pour l'administration parentérale de composés et leurs utilisations
WO2008097561A8 (fr) Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
WO2005111039A3 (fr) Composés et procée pour l'inhibition de progression mitotique
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2008153705A3 (fr) Procédés de traitement, de diagnostic et de détection de troubles liés à fgf21
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
WO2008073452A8 (fr) Compositions, synthèse et procédés d'utilisation d'inhibiteurs de cholinestérase à base d'indanone
WO2009050136A3 (fr) Procédé de traitement du syndrome de cushing
WO2008061720A3 (fr) Utilisation de diterpènes tricycliques et leurs dérivés pour le traitement, le cotraitement ou la prévention de troubles inflammatoires et/ou troubles des articulations
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
IL195217A0 (en) Protein kinase inhibitors and uses thereof
TNSN08191A1 (en) Kinase inhibitors
WO2008034142A3 (fr) Synthèse, procédés d'utilisation et compositions de cycloalkylméthylamines
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007871986

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12312774

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871986

Country of ref document: EP

Kind code of ref document: A2